Nabumetone vs Diclofenac — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Nonsteroidal Anti-inflammatory Drug

Nabumetone

Brand: RELAFEN DS

First FDA approval: 2002-02-25

Nonsteroidal Anti-inflammatory Drug

Diclofenac

Brand: Cambia

First FDA approval: 1996-03-26

Lowest NADACAcquisition cost floor across all NDCs

$0.128Per unit

$0.069Per unit

Average NADACAcross all dosage forms and strengths

$2.40Up to $31.67

$2.11Up to $16.44

Generic manufacturersActive ANDA holders — FDA Orange Book

817 total ANDAs filed

4164 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$20.7MFull year

$610.4MFull year

Part D claims (CY24)Total fills, all strengths

865K353K beneficiaries

9.4M3.8M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$24Per claim, all NDCs

$65Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

275Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

21Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes8 manufacturers

Yes41 manufacturers